These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 18690997)

  • 1. Skeletal effects of drugs to treat cancer.
    Vestergaard P
    Curr Drug Saf; 2008 Sep; 3(3):173-7. PubMed ID: 18690997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230).
    Eastell R; Hannon RA; Cuzick J; Dowsett M; Clack G; Adams JE;
    J Bone Miner Res; 2006 Aug; 21(8):1215-23. PubMed ID: 16869719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of joint symptoms and bone fractures in Japanese postmenopausal breast cancer patients treated with adjuvant anastrozole.
    Okishiro M; Taguchi T; Kim SJ; Tanji Y; Shimazu K; Tamaki Y; Noguchi S
    J Cancer Res Clin Oncol; 2009 Jun; 135(6):823-7. PubMed ID: 19034512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone safety of aromatase inhibitors versus tamoxifen.
    Lønning PE
    Int J Gynecol Cancer; 2006; 16 Suppl 2():518-20. PubMed ID: 17010062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in bone mineral density after adjuvant aromatase inhibitors and fracture risk in breast cancer patients.
    Berruti A; Tucci M; Mosca A; Vana F; Ardine M; Dogliotti L; Angeli A; Bertoldo F
    J Clin Oncol; 2007 Apr; 25(11):1455-6. PubMed ID: 17416873
    [No Abstract]   [Full Text] [Related]  

  • 6. Aromatase inhibitors and their future role in post-menopausal women with early breast cancer.
    Lønning PE
    Br J Cancer; 1998 Sep; 78 Suppl 4(Suppl 4):12-5. PubMed ID: 9741783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term outcomes of aromatase inhibition for breast cancer.
    Toi M
    Lancet Oncol; 2008 Jan; 9(1):8-10. PubMed ID: 18177815
    [No Abstract]   [Full Text] [Related]  

  • 8. Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial.
    Van Poznak C; Hannon RA; Mackey JR; Campone M; Apffelstaedt JP; Clack G; Barlow D; Makris A; Eastell R
    J Clin Oncol; 2010 Feb; 28(6):967-75. PubMed ID: 20065185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aromatase inhibitor-induced bone mineral loss and its prevention by bisphosphonate administration in postmenopausal breast cancer patients.
    Yonehara Y; Iwamoto I; Kosha S; Rai Y; Sagara Y; Douchi T
    J Obstet Gynaecol Res; 2007 Oct; 33(5):696-9. PubMed ID: 17845332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group.
    Gnant MF; Mlineritsch B; Luschin-Ebengreuth G; Grampp S; Kaessmann H; Schmid M; Menzel C; Piswanger-Soelkner JC; Galid A; Mittlboeck M; Hausmaninger H; Jakesz R;
    J Clin Oncol; 2007 Mar; 25(7):820-8. PubMed ID: 17159195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Managing bone health in women with breast cancer under adjuvant treatment with aromatase inhibitors: pretreatment bone mineral density is important.
    Markopoulos C
    Breast Cancer Res; 2010; 12(4):403. PubMed ID: 20727234
    [No Abstract]   [Full Text] [Related]  

  • 12. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates.
    Confavreux CB; Fontana A; Guastalla JP; Munoz F; Brun J; Delmas PD
    Bone; 2007 Sep; 41(3):346-52. PubMed ID: 17618847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of exemestane, anastrozole and tamoxifen on bone mineral density and bone turnover markers in postmenopausal early breast cancer patients: results of N-SAS BC 04, the TEAM Japan substudy.
    Aihara T; Suemasu K; Takei H; Hozumi Y; Takehara M; Saito T; Ohsumi S; Masuda N; Ohashi Y
    Oncology; 2010; 79(5-6):376-81. PubMed ID: 21430407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy: a 5-year follow-up.
    Majithia N; Atherton PJ; Lafky JM; Wagner-Johnston N; Olson J; Dakhil SR; Perez EA; Loprinzi CL; Hines SL
    Support Care Cancer; 2016 Mar; 24(3):1219-26. PubMed ID: 26298334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anastrozole for breast cancer: recent advances and ongoing challenges.
    Buzdar AU
    Expert Rev Anticancer Ther; 2006 Jun; 6(6):839-48. PubMed ID: 16761927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aromatase inhibitors and bone health.
    Bundred NJ
    Curr Opin Obstet Gynecol; 2009 Feb; 21(1):60-7. PubMed ID: 19125005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial.
    Jakesz R; Jonat W; Gnant M; Mittlboeck M; Greil R; Tausch C; Hilfrich J; Kwasny W; Menzel C; Samonigg H; Seifert M; Gademann G; Kaufmann M; Wolfgang J;
    Lancet; 2005 Aug 6-12; 366(9484):455-62. PubMed ID: 16084253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aromatase inhibitors: treatment of advanced breast cancer.
    Panasci LC
    J Clin Oncol; 2001 Oct; 19(19):3999-4000. PubMed ID: 11579125
    [No Abstract]   [Full Text] [Related]  

  • 19. Bone density in breast cancer: when to intervene?
    Gralow JR
    J Clin Oncol; 2007 Aug; 25(22):3194-7. PubMed ID: 17577014
    [No Abstract]   [Full Text] [Related]  

  • 20. Is long-term adjuvant treatment of breast cancer with anastrozole indicated?
    Doggrell SA
    Expert Opin Pharmacother; 2008 Jun; 9(9):1619-22. PubMed ID: 18518790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.